Development Pipeline
  Commercial Products
  Research Programs







Product: Remoxy®
NDA
Indication: Chronic Pain
Drug: Oxycodone
Partner: King Pharmaceuticals and Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)

Product: POSIDUR™
Phase II
Indication: Post-Operative Pain
Drug: Bupivacaine
Partner: Nycomed (Europe, CIS)
Technology: SABER Delivery System (injectable)

Product: TRANSDUR™ Sufentanil
Phase I
Indication: Chronic Pain
Drug: Sufentanil
Partner: Worldwide rights held by DURECT
Technology: TRANSDUR

Product: ELADUR™ (TRANSDUR-Bupivacaine)
Phase I
Indication: Post-Herpetic Neuralgia
Drug: Bupivacaine
Partner: Alpharma (now King Pharmaceuticals)
Technology: TRANSDUR

Product: Undisclosed Oral Opioid #1
Phase I
Indication: Chronic Pain
Drug: Undisclosed
Partner: King Pharmaceuticals and Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)

Product: Undisclosed Oral Opioid #2
Phase I
Indication: Chronic Pain
Drug: Undisclosed
Partner: King Pharmaceuticals and Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)


 
 © 2000-2010 DURECT Corporation
Last updated: July 29, 2010
Search     Contact     Site Index     Legal Notice     Privacy Policy